8-K: Exagen Reports Record Q2 Revenue, Strengthens Balance Sheet with $20.2M Capital Raise

Exagen Inc. announced record second-quarter 2025 revenue of $17.2 million, representing 14% year-over-year growth, alongside a $20.2 million public stock offering and new loan facility to bolster its financial position.

Summary

• Achieved record total revenue of $17.2 million for Q2 2025, marking an 11% increase from Q1 2025 and 14% growth compared to Q2 2024.
• AVISE CTD test volume grew 14% quarter-over-quarter and 7% year-over-year.
• Expanded AVISE CTD trailing twelve-month average selling price (ASP) to $428, an increase of $27 per test over Q2 2024.
• Reported a net loss of $(4.439) million for Q2 2025, compared to $(2.966) million in Q2 2024.
• Adjusted EBITDA for Q2 2025 was $(1.721) million, compared to $(1.598) million in Q2 2024.
• Ended Q2 2025 with cash, cash equivalents, and restricted cash of $30.2 million.
• Successfully closed a $20.2 million public offering of common stock and secured a new loan credit facility.
• Appointed Dr. Michael Mahler as Chief Scientific Officer and welcomed Chas McKhann to the Board of Directors.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to strong revenue growth, increased test volumes and ASP, and a significantly strengthened balance sheet through a successful capital raise. While net losses persist, the clear path to potential positive adjusted EBITDA by Q4 2025 and strategic leadership additions contribute to a favorable outlook.

Positives

• Record total revenue of $17.2 million in Q2 2025, demonstrating strong top-line growth of 14% year-over-year.
• Significant growth in AVISE CTD test volume, up 14% from Q1 2025 and 7% from Q2 2024, indicating increasing market adoption.
• Increased AVISE CTD trailing twelve-month average selling price (ASP) to $428, a $27 improvement over Q2 2024, suggesting better pricing power or mix.
• Strengthened balance sheet with $30.2 million in cash, cash equivalents, and restricted cash at quarter-end, supported by a $20.2 million public offering and new loan facility.
• Strategic appointments of Dr. Michael Mahler as Chief Scientific Officer and Chas McKhann to the Board of Directors enhance leadership and expertise.

Negatives

• Net loss increased to $(4.439) million in Q2 2025 from $(2.966) million in Q2 2024.
• Operating loss increased to $(2.630) million in Q2 2025 from $(2.587) million in Q2 2024.
• Adjusted EBITDA remained negative at $(1.721) million in Q2 2025, a slight increase in negative value from $(1.598) million in Q2 2024.
• Operating expenses increased to $13.025 million in Q2 2025 from $11.643 million in Q2 2024.

Risks

• Delays in reimbursement and coverage decisions from Medicare and third-party payors.
• Interactions with regulatory authorities could impact operations.
• Delays in ongoing and planned clinical trials involving testing products.
• Potential effects of inflation and tariffs on the company's margins.
• Changes in laws and regulations related to regulatory requirements.
• Commercial success is dependent on attaining and maintaining significant market acceptance of testing products among rheumatologists, patients, and payors.
• Third-party payors may not provide coverage and adequate reimbursement for testing products, affecting the ability to collect on funds due.
• Ability to obtain and maintain intellectual property protection for testing products is crucial.
• Regulatory developments could adversely affect the business.

Future Outlook

The company expects full-year 2025 revenue to be between $65 million and $70 million. Management anticipates achieving positive adjusted EBITDA in the fourth quarter of 2025, provided revenue reaches the high end of this guidance range.

Management Comments

• The company delivered record total revenue of $17.2 million in Q2 2025, reflecting strong growth.
• AVISE CTD test volume and average selling price continue to expand, indicating positive market traction.
• The balance sheet has been strengthened through a successful public offering and new loan facility, providing financial flexibility.
• Strategic appointments to the leadership team and Board of Directors are expected to enhance scientific and executive capabilities.

Industry Context

Exagen operates in the autoimmune diagnostics sector, a growing field driven by increasing prevalence of autoimmune diseases and demand for earlier, more accurate diagnosis. The company's focus on its flagship AVISE CTD test positions it within the specialized rheumatic disease testing market. The reported revenue growth and increased test volumes suggest strong performance relative to general market trends, while the continued net losses are common for growth-stage diagnostic companies investing heavily in market penetration and R&D.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or industry benchmarks to allow for a detailed assessment against global standards. However, the reported 14% year-over-year revenue growth and 7% increase in AVISE CTD test volume indicate robust performance within the specialized autoimmune diagnostics market.
• The increase in average selling price (ASP) for AVISE CTD to $428 suggests potential pricing power or a favorable shift in test mix, which could be a positive differentiator compared to competitors in the diagnostic space.
• While the company continues to report net losses and negative adjusted EBITDA, this is not uncommon for innovative diagnostic companies in growth phases that are investing in market expansion and product development. Achieving positive adjusted EBITDA by Q4 2025, as guided, would be a significant milestone for a company of this size in the diagnostics industry.

Management Changes

Stakeholder Impact

• Shareholders: Potential for increased value due to strong revenue growth, strategic appointments, and a strengthened balance sheet, though continued losses may temper immediate returns. The capital raise dilutes existing shares but provides necessary funding for growth.
• Customers (Clinicians and Patients): Continued availability and expansion of AVISE CTD testing solutions, potentially leading to improved diagnostic clarity and clinical outcomes for autoimmune conditions.
• Employees: New leadership appointments may bring new strategic direction and opportunities, while continued growth could lead to job stability or expansion.
• Creditors: The new loan credit facility indicates continued access to debt financing, and the strengthened cash position improves the company's ability to meet its obligations.

Next Steps

• Host a conference call on July 29, 2025, at 8:30 a.m. ET to review Q2 2025 financial results and provide a business update.
• Work towards achieving full-year 2025 revenue guidance of $65 million to $70 million.
• Focus on reaching positive adjusted EBITDA in the fourth quarter of 2025, particularly if revenue hits the high end of the guidance range.

Key Dates

Recommendation

Exagen demonstrates strong top-line growth with record revenue and increasing test volumes, indicating solid market penetration for its autoimmune diagnostic solutions. The successful $20.2 million capital raise significantly strengthens the balance sheet, providing crucial liquidity for ongoing operations and growth initiatives. However, the company continues to incur net losses and negative adjusted EBITDA, which increased year-over-year. While management projects positive adjusted EBITDA by Q4 2025 at the high end of revenue guidance, this remains a forward-looking statement. The stock is a 'hold' for investors who recognize the significant growth potential in the autoimmune diagnostics market and the company's execution on its strategic plan, but also acknowledge the continued unprofitability and associated risks. A 'buy' might be considered for those with higher risk tolerance and a longer investment horizon, contingent on the company's ability to achieve its profitability targets.

Keywords

Autoimmune diagnostics, AVISE CTD, Rheumatic diseases, SEC filing, Financial results, Revenue growth, Net loss, EBITDA, Cash position, Capital raise, Biotechnology, Medical testing, Diagnostics